Mucosal healing in Crohn's disease: Relevance for clinical outcomes

Current Drug Targets

Volumn 13, Issue 10, 2012, Pages 1248-1251

  Löwenberg, Mark ^a   D'Haens, Geert ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Anti tumor necrosis factor (TNF) agents; Biologicals; Crohn's disease (CD); Immunomodulators; Long term disease course; Mucosal healing

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; CERTOLIZUMAB PEGOL; INFLIXIMAB; LACTOFERRIN;

ARTICLE; CAPSULE ENDOSCOPY; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOSCOPY; FECES LEVEL; FOLLOW UP; HEALING; HUMAN; MUCOSAL HEALING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; RELAPSE; REMISSION; TREATMENT OUTCOME;

CROHN DISEASE; HUMANS; INTESTINAL MUCOSA; MONITORING, PHYSIOLOGIC; TREATMENT OUTCOME;

EID: 84866547658     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012802429688     Document Type: Article

References (22)

1. Farmer RG, Hawk WA, Turnbull RB, Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975; 68: 627-35.
2. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50.
3. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011; 17: 1415-22.
4. Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102: 1647-53.
5. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15: 1295-301.
6. Baert F, Moortgat L, van AG, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-8.
7. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
8. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 97: 947-53.
9. af Bjorkesten CG, Nieminen U, Turunen U, Arkkila PE, Sipponen T, Farkkila MA. Endoscopic monitoring of infliximab therapy in Crohn's disease. Inflamm Bowel Dis 2011; 17: 947-53.
10. Jurgens M, Mahachie John JM, Cleynen I, et al. Levels of Creactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9: 421-7.
11. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13.
12. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30: 983-9.
13. Daperno M, D'Haens G, van AG, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12.
14. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-63.
15. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
16. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2011; 142(1): 63-70.
17. Rimola J, Rodriguez S, Garcia-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009; 58: 1113-20.
18. Sipponen T, Savilahti E, Karkkainen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008; 14: 1392-8.
19. Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008; 14: 85-9.
20. Sandor KL, Papp M, Dorottya LB, et al. High-sensitivity Creactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: A marker for patient classification? Inflamm Bowel Dis 2011. doi: 10.1002/ibd.21933 [Epub ahead of print].
21. Geboes K, Dalle I. Influence of treatment on morphological features of mucosal inflammation. Gut 2002; 50 Suppl 3: III37-III42.
22. Geboes K, Rutgeerts P, Opdenakker G, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 2005; 21: 1741-54.